20/20 Biolabs, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 20/20 Biolabs, Inc. (Nasdaq: AIDX) on May 26, 2026, reporting an event that occurred on May 19, 2026. The Company is incorporated in Delaware and is designated as an Emerging Growth Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On May 19, 2026, the Board of Directors adopted Amendment No. 1 to the Company's Amended and Restated Bylaws. The material change involves Section 2.5 of the Bylaws, which reduces the quorum required for a meeting of stockholders from a majority of the shares outstanding to one-third of the shares outstanding.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural amendment of the Bylaws.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 to the Amended and Restated Bylaws filed as Exhibit 3.2.
- Confirm the impact of the reduced quorum requirement (one-third of shares) on future shareholder meeting outcomes.
- Review the Company's most recent Form 1-K or 10-Q for current financial metrics, as this 8-K does not include them.